B95
Conditions
Interventions
Group 1: Continuous infusion of vancomycin with vancomycin serum levels in the range of 15-25 mg/dl on the second day of vancomycin therapy and averaged over the course of therapy
Group 2: Continuous
Sponsors
Lehrstuhl für Hygiene und Umweltmedizin, Department für Humanmedizin, Fakultät für Gesundheit
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: All patients >/= 18 years of age admitted to the surgical intensive care unit (OITS) of the hospitals of the city of Cologne, who received vancomycin as continuous infusion and for whom at least one vancomycin serum level within the reference range was available (either d2: 15-20 mg/L or 25-30 mg/L; or mean vancomycin serum level: 15-20 mg/L or 25-30 mg/L).
Exclusion criteria
Exclusion criteria: Patients < 18 years; internal medicine patients; intermittent vancomycin therapy; change of vancomycin infusion modality (intermittent/continuous); therapy duration < 2 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy outcome measure is all-cause mortality in the intensive care unit (ICU). The primary toxicity outcome measure is the incidence of nephrotoxicity, defined as acute kidney injury (AKI) according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria during ICU stay. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary efficacy endpoints will include treatment failure and treatment success. Secondary safety endpoints will include time to nephrotoxicity, duration of nephrotoxicity, reversibility of nephrotoxicity and risk factors for nephrotoxicity. | — |
Countries
Germany
Contacts
Public ContactKatrin Viertel
Zentralapotheke Kliniken der Stadt Köln
Outcome results
None listed